

15<sup>th</sup> International Conference on **Surgical Pathology and Cancer Diagnosis**

&amp;

4<sup>th</sup> International Conference on **General Practice & Primary Care**

April 15-16, 2019 Berlin, Germany



## *Helle Fisker*

*BioBrandAware, Denmark*

### **Digital pathology as a resource for surgical pathology**

Right now, a wave of powerful digital pathology technologies poised to disrupt the field of pathology. As a surgical pathologist, you should not feel threatened by these changes. It will elevate the role of the pathologist to take more strategic decisions based on data, output and input parameters. The advantages of applying digital technologies are many: Saving time with well-structured digital workflow technologies; Working closely and more efficiently with remote colleagues or peers; Getting more work done by implementing; Augmented pathology based on image analysis (IA) or artificial intelligence (AI) to enhance and assist interpretation; AI and deep learning-based algorithms for counting or interpretation; Machine learning for improved accuracy; Ensuring work is performed in concordance with the latest standards; Cost-optimizing as has been demonstrated in several studies lately. However implementing it may appear overwhelming and cost adding. Existing scanner capabilities and software applications have improved tremendously in speed over the past years. Storage has become cheaper. For the future, it is predicted that AI will be the most disruptive class of technologies in the world over the next 10 years due to radical computational power. The challenge is to predict which are of the future pathology applications are worth implementing? The good news is that a full digitalization of workflow is not necessary to obtain the first benefits of digital pathology. A simple IMS is the key. Be aware it must be able to connect to the latest and greatest future applications. That will put you in the driver's seat deciding when relevant to take the next step of the digital journey. This presentation will provide an overview of the market and a discussion of where it is heading along with suggestions for how to best approach implementation challenges.



## JOINT EVENT

15<sup>th</sup> International Conference on **Surgical Pathology and Cancer Diagnosis**

&

4<sup>th</sup> International Conference on **General Practice & Primary Care**

April 15-16, 2019 Berlin, Germany

---

### Recent Publications

1. Malin Rundgren, Stig Lyngbaek, Helle Fisker and Hans Friberg (2015) The inflammatory marker suPAR after cardiac arrest. *Therapeutic Hypothermia and Temperature Management* 5(2):89-94.

### Biography

Helle Fisker has completed her MSc at the Technical University of Denmark. She has more than 15 years of global product marketing experience for cancer research, diagnostic, predictive and prognostic cancer biomarkers as well as infectious diseases. For the past 10 years she is heading up marketing activities in established cancer diagnostic companies as well as rapidly growing new technology start-up companies. For the past 10 years she is heading up marketing departments of pathology companies Dako, LeicaBiosystems and Visiopharm. Currently, she is working as a Consultant to companies with an ambition to digitize anatomic pathology and in parallel, she is working to achieve the EMBA degree from Copenhagen Business School, which is done with a focus on digital pathology.

[helle@biobrandaware.com](mailto:helle@biobrandaware.com)

### Notes: